Treatment of elderly patients with glioblastoma: From clinical evidence to molecular highlights

Cancer Treatment Reviews

Volumn 38, Issue 8, 2012, Pages 988-995

  Chargari, Cyrus ^a   Feuvret, Loïc ^b   Bauduceau, Olivier ^a   Ricard, Damien ^a,b   Cuenca, Xavier ^b   Delattre, Jean Yves ^b   Mazeron, Jean Jacques ^b  

^a University of Paris Descartes   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Elderly patients; Glioblastoma; Radiotherapy; Surgery; Targeted therapies; Temozolomide

Indexed keywords

AMINOLEVULINIC ACID; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; IRINOTECAN; LOMUSTINE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METALLOPROTEINASE INHIBITOR; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NITROSOUREA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE INHIBITOR; PHOSPHOPROTEIN PHOSPHATASE INHIBITOR; PLATELET DERIVED GROWTH FACTOR INHIBITOR; PROCARBAZINE; PROTEIN TYROSINE KINASE INHIBITOR; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; VINCRISTINE;

AGED; BLOOD TOXICITY; BRAIN BIOPSY; BRAIN HEMORRHAGE; CANCER ADJUVANT THERAPY; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CHROMOSOME 10Q; CHROMOSOME 19Q; CHROMOSOME 1P; COGNITION; CRANIOTOMY; CYTOREDUCTIVE SURGERY; DELAYED NEUROTOXICITY; DNA METHYLATION; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; FUNCTIONAL STATUS; GENE EXPRESSION; GENE MUTATION; GENETIC MARKER; GERIATRIC PATIENT; GLIOBLASTOMA; HETEROZYGOSITY LOSS; HUMAN; HYPOFRACTIONATED RADIOTHERAPY; KARNOFSKY PERFORMANCE STATUS; MEDICAL DECISION MAKING; MEDICAL LITERATURE; MENTAL DETERIORATION; MICROSURGERY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTOPERATIVE CARE; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION SICKNESS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SHORT COURSE THERAPY; SIGNAL TRANSDUCTION; STEREOTACTIC BIOPSY; SURVIVAL RATE; SURVIVAL TIME; TELOMERE; THROMBOEMBOLISM; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE; UNSPECIFIED SIDE EFFECT;

AGE FACTORS; AGED; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; GLIOBLASTOMA; HUMANS; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 84867203245     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2011.12.010     Document Type: Review

References (84)

1. Werner M.H., Phuphanich S., Lyman G.H. The increasing incidence of malignant gliomas and primary central nervous system lymphoma in the elderly. Cancer 1995, 76:1634-1642.
2. Meckling S., Dold O., Forsyth P.A.J., et al. Malignant supratentorial glioma in the elderly: is RT useful?. Neurology 1996, 47:901-905.
3. Halperin E.C. Malignant gliomas in older adults with poor prognostic signs: getting nowhere, and taking a long time to do it. Oncology 1995, 9:229-234.
4. Walker M.D., Alexander E., Hunt W.E., et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 1978, 49:333-343.
5. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996.
6. Lanzetta G., Minniti G. Treatment of glioblastoma in elderly patients: an overview of current treatments and future perspective. Tumori 2010, 96:650-658.
7. Chaichana K.L., Chaichana K.K., Olivi A., et al. Surgical outcomes for older patients with glioblastoma multiforme: preoperative factors associated with decreased survival. Clinical article. J Neurosurg 2011, 114:587-594.
8. Kreth F.W., Warnke P.C., Scheremet R., Ostertag C.B. Surgical resection and radiation therapy vs biopsy and radiation therapy in the treatment of glioblastoma multiforme. J Neurosurg 1993, 78:762-766.
9. Kelly P.J., Hunt C. The limited value of cytoreductive surgery in elderly patients with malignant gliomas. Neurosurgery 1994, 34:62-66.
10. Ewelt C., Goeppert M., Rapp M., Steiger H.J., Stummer W., Sabel M. Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival. J Neurooncol 2011, 103:611-618.
11. Scott J., Tsai Y.Y., Chinnaiyan P., Yu H.H. Effectiveness of Radiotherapy for Elderly Patients with Glioblastoma. Int J Radiat Oncol Biol Phys 2011, 81:206-210.
12. Vuorinen V., Hinkka S., Färkkilä M., Jääskeläinen J. Debulking or biopsy of malignant glioma in elderly people - a randomised study. Acta Neurochir (Wien) 2003, 145:5-10.
13. Stummer W., Pichlmeier U., Meinel T., Wiestler O.D., Zanella F., Reulen H.J. ALA Glioma Study Group. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 2006, 7:392-401.
14. Iwamoto F.M., Cooper A.R., Reiner A.S., Nayak L., Abrey L.E. Glioblastoma in the elderly: the Memorial Sloan-Kettering Cancer Center Experience (1997-2007). Cancer 2009, 115:3758-3766.
15. Stark A.M., Hedderich J., Held-Feindt J., Mehdorn H.M. Glioblastoma-the consequences of advanced patient age on treatment and survival. Neurosurg Rev 2007, 30:56-61.
16. Mangiola A., Maira G., De Bonis P., Porso M., Pettorini B., Sabatino G., et al. Glioblastoma multiforme in the elderly: a therapeutic challenge. J Neurooncol 2006, 76:159-163.
17. Keime-Guibert F., Chinot O., Taillandier L., et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med 2007, 356:1527-1535.
18. Soussain C., Ricard D., Fike J.R., Mazeron J.J., Psimaras D., Delattre J.Y. CNS complications of radiotherapy and chemotherapy. Lancet 2009, 374:1639-1651.
19. Brown P.D., Jensen A.W., Felten S.J., et al. Detrimental effects of tumor progression on cognitive function of patients with high-grade glioma. J Clin Oncol 2006, 24:5427-5433.
20. Hegi M.E., Diserens A.C., Gorlia T., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352:997-1003.
21. Stupp R., Hegi M.E., Mason W.P., et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009, 10:459-466.
22. Stummer W., Nestler U., Stockhammer F., et al. Favorable outcome in the elderly cohort treated by concomitant temozolomide radiochemotherapy in a multicentric phase II safety study of 5-ALA. J Neurooncol 2011, 103:361-370.
23. Gerstein J., Franz K., Steinbach J.P., Seifert V., Fraunholz I., Weiss C., et al. Postoperative radiotherapy and concomitant temozolomide for elderly patients with glioblastoma. Radiother Oncol 2010, 97:382-386.
24. Fiorica F., Berretta M., Colosimo C., et al. Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with concomitant temozolomide. Arch Gerontol Geriatr 2010, 51:31-35.
25. Combs S.E., Wagner J., Bischof M., et al. Postoperative treatment of primary glioblastoma multiforme with radiation and concomitant temozolomide in elderly patients. Int J Radiat Oncol Biol Phys 2008, 70:987-992.
26. Kimple R.J., Grabowski S., Papez M., Collichio F., Ewend M.G., Morris D.E. Concurrent temozolomide and radiation, a reasonable option for elderly patients with glioblastoma multiforme?. Am J Clin Oncol 2010, 33:265-270.
27. Brandes A.A., Franceschi E., Tosoni A., et al. Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. Cancer 2009, 115:3512-3518.
28. Minniti G., Salvati M., Arcella A., et al. Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide. J Neurooncol 2011, 102:311-316.
29. Gerstner E.R., Yip S., Wang D.L., Louis D.N., Iafrate A.J., Batchelor T.T. MGMT methylation is a prognostic biomarker in elderly patients with newly diagnosed glioblastoma. Neurology 2009, 73:1509-1510.
30. Minniti G., De Sanctis V., Muni R., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients. J Neurooncol 2008, 88:97-103.
31. Patwardhan R.V., Shorter C., Willis B.K., et al. Survival trends in elderly patients with glioblastoma multiforme: resective surgery, radiation, and chemotherapy. Surg Neurol 2004, 62:207-213.
32. Bleehen N.M., Stenning S.P. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. Br J Cancer 1991, 64:769-774.
33. Lopez S., Taillibert S., Idbaih A., Simon J.M., Mazeron J.J. Should elderly patients with glioblastoma be proposed to radiotherapy?. Cancer Radiother 2008, 12:827-830.
34. Branislav J., Shibamoto Y., Grujicic D., et al. Short-course RT in elderly and frail patients with glioblastoma multiforme: a phase II study. J Neurooncol 1999, 44:85-90.
35. Thomas R., James N., Guerrero D., et al. Hypofractionated RT as palliative treatment in poor prognosis patients with high-grade glioma. Radiother Oncol 1994, 33:113-116.
36. Clarke J.W., Chang E.L., Levin V.A., et al. Optimizing RT schedules for elderly glioblastoma multiforme patients. Expert Rev Anticancer Ther 2008, 8:733-741.
37. Roa W., Xing J.Z., Small C., Kortmann R., et al. Current developments in the RT approach to elderly and frail patients with glioblastoma multiforme. Expert Rev Anticancer Ther 2009, 9:1643-1650.
38. Phillips C., Guiney M., Smith J., Hughes P., Narayan K., Quong G. A randomized trial comparing 35Gy in ten fractions with 60Gy in 30 fractions of cerebral irradiation for glioblastoma multiforme and older patients with anaplastic astrocytoma. Radiother Oncol 2003, 68:23-26.
39. Hoegler D.B., Davey P. A prospective study of short course RT in elderly patients with malignant glioma. J Neurooncol 1997, 33:201-204.
40. Bauman G.S., Gaspar L.E., Fisher B.J., Halperin E.C., Macdonald D.R., Cairncross J.G. A prospective study of short-course radiotherapy in poor prognosis glioblastoma multiforme. Int J Radiat Oncol Biol Phys 1994, 29:835-839.
41. Jeremic B., Shibamoto Y., Grujicic D., et al. Short-course radiotherapy in elderly and frail patients with glioblastoma multiforme. A phase II study. J Neurooncol 1999, 44:85-90.
42. Chang E.L., Yi W., Allen P.K., Levin V.A., Sawaya R.E., Maor M.H. Hypofractionated radiotherapy for elderly or younger low-performance status glioblastoma patients: outcome and prognostic factors. Int J Radiat Oncol Biol Phys 2003, 56:519-528.
43. Roa W., Brasher P.M., Bauman G., et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 2004, 22:1583-1588.
44. Minniti G., De Sanctis V., Muni R., et al. Hypofractionated radiotherapy followed by adjuvant chemotherapy with temozolomide in elderly patients with glioblastoma. J Neurooncol 2009, 91:95-100.
45. http://clinicaltrials.gov/ct2/show/NCT00482677?term=NCT00482677&rank =1.
46. Villa S., Vinolas N., Verger E., et al. Efficacy of radiotherapy for malignant gliomas in elderly patients. Int J Radiat Oncol Biol Phys 1998, 42:977-980.
47. Glantz M., Chamberlain M., Liu Q., Litofsky N.S., Recht L.D. Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas. Cancer 2003, 97:2262-2266.
48. Chinot O.L., Barrie M., Frauger E., et al. Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations. Cancer 2004, 100:2208-2214.
49. Laigle-Donadey F., Figarella-Branger D., Chinot O., et al. Up-front temozolomide in elderly patients with glioblastoma. J Neurooncol 2010, 99:89-94.
50. Ducray F., del Rio M.S., Carpentier C., et al. Up-front temozolomide in elderly patients with anaplastic oligodendroglioma and oligoastrocytoma. J Neurooncol 2011, 101:457-462.
51. Wick W., Engel C., Combs S.E., Nikkhah G., et al. NOA-08 randomized phase III trial of 1-week-on/1-week-off temozolomide vs involved-field radiotherapy in elderly (older than age 65) patients with newly diagnosed anaplastic astrocytoma or glioblastoma (Methusalem). J Clin Oncol 2010, 28:18. [Abst LBA2001].
52. Malmstrom A., Grønberg B.H., Stupp R., et al. Glioblastoma (GBM) in elderly patients: a randomized phase III trial comparing survival in patients treated with 6-week radiotherapy (RT) vs hypofractionated RT over 2 weeks vs temozolomide single-agent chemotherapy (TMZ). J Clin Oncol 2010, 28:18. [Abst LBA 2002].
53. Gállego Pérez-Larraya J., Ducray F., et al. Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial. J Clin Oncol 2011, 29:3050-3055.
54. Grant R., Liang B.C., Page M.A., Crane D.L., Greenberg H.S., Junck L. Age influences chemotherapy response in astrocytomas. Neurology 1995, 45:929-933.
55. Pierga J.Y., Hoang-Xuan K., Feuvret L., et al. Treatment of malignant gliomas in the elderly. J Neurooncol 1999, 43:187-193.
56. Brandes A.A., Vastola F., Basso U. A prospective study in glioblastoma multiforme. Cancer 2003, 3:657-662.
57. Vredenburgh J.J., Desjardins A., Herndon J.E., et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007, 25:4722-4729.
58. Vredenburgh J.J., Desjardins A., Herndon J.E., et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007, 13:1253-1259.
59. Desjardins A., Reardon D.A., Herndon J.E., et al. Bevacizumab Plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res 2008, 14:7068-7073.
60. Friedman H.S., Prados M.D., Wen P.Y., et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009, 27:4733-4740.
61. http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInform ationforPatientsandProviders/UCM237171.pdf.
62. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_R eport_-_Variation/human/000582/WC500075000.pdf.
63. http://clinicaltrials.gov/ct2/show/NCT01149850.
64. https://icrepec.afssaps.fr/Public/essaiDesc.php.
65. Chauffert B., Feuvret L., Bonnetain F., et al. Randomized multicenter phase II trial of irinotecan and bevacizumab as neoadjuvant and adjuvant to temozolomide-based chemoradiation versus chemoradiation for unresectable glioblastoma: interim results of the TEMAVIR study from the ANOCEF group. J Clin Oncol 2011, 29. [Abst 2029].
66. Lutterbach J., Bartelt S., Momm F., Becker G., Frommhold H., Ostertag C. Is older age associated with a worse prognosis due to different patterns of care? A long-term study of 1346 patients with glioblastomas or brain metastases. Cancer 2005, 103:1234-1244.
67. Felsberg J., Rapp M., Loeser S., et al. Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients. Clin Cancer Res 2009, 15:6683-6693.
68. Batchelor T.T., Betensky R.A., Esposito J.M., et al. Age-dependent prognostic effects of genetic alterations in glioblastoma. Clin Cancer Res 2004, 10:228-233.
69. Ohgaki H., Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol (Berl) 2005, 109:93-108.
70. Kleinschmidt-DeMasters B.K., Lillehei K.O., Varella-Garcia M. Glioblastomas in the older old. Arch Pathol Lab Med 2005, 129:624-631.
71. Xie D., Zeng Y.X., Wang H.J., et al. Amplification and overexpression of epidermal growth factor receptor gene in glioblastomas of Chinese patients correlates with patient's age but not with tumor's clinicopathological pathway. Acta Neuropathol 2005, 110:481-489.
72. Mischel P.S., Cloughesy T.F. Targeted molecular therapy of GBM. Brain Pathol 2003, 13:52-61.
73. Rich J.N., Reardon D.A., Peery T., Dowell J.M., Quinn J.A., Penne K.L., et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004, 22:133-142.
74. Prados M.D., Lamborn K.R., Chang S., et al. Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro Oncol 2006, 8:67-78.
75. Nakamura M., Watanabe T., Yonekawa Y., Kleihues P., Ohgaki H. Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C→A:T mutations of the TP53 tumor suppressor gene. Carcinogenesis 2001, 22:1715-1719.
76. Paz M.F., Yaya-Tur R., Rojas-Marcos I., et al. CpG Island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 2004, 10:4933-4938.
77. Verhaak R.G., Hoadley K.A., Purdom E., et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17:98-110.
78. Hartmann C., Hentschel B., Wick W., et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 2010, 120:707-718.
79. Nobusawa S., Watanabe T., Kleihues P., Ohgaki H. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 2009, 15:6002-6007.
80. McDonald K.L., McDonnell J., Muntoni A., et al. Presence of alternative lengthening of telomeres mechanism in patients with glioblastoma identifies a less aggressive tumor type with longer survival. J Neuropathol Exp Neurol 2010, 69:729-736.
81. Lee Y., Scheck A.C., Cloughesy T.F., Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. BMC Med Genomics 2008, 1:52.
82. Freije W.A., Castro-Vargas F.E., Fang Z., et al. Gene expression profiling of gliomas strongly predicts survival. Cancer Res 2004, 64:6503-6510.
83. Muacevic A., Kreth F.W. Quality-adjusted survival after tumor resection and/or radiation therapy for elderly patients with glioblastoma multiforme. J Neurol 2003, 250:561-568.
84. Iwamoto F.M., Reiner A.S., Panageas K.S., Elkin E.B., Abrey L.E. Patterns of care in elderly glioblastoma patients. Ann Neurol 2008, 64:628-634.